Evogene Ltd. (EVGN)

Evogene Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-21.47	-23.88	-26.64	-27.79	-23.37	-18.11
Depreciation & Amortization	2.64	2.61	2.58	2.23	2.73	2.77
Share-Based Compensation	2	1.88	1.19	2.61	4.1	1.58
Other Operating Activities	-2.61	-2.19	-0.81	-1.77	-2.96	-3.9
Operating Cash Flow	-19.44	-21.58	-23.68	-24.72	-19.51	-17.67
Capital Expenditures	-0.56	-0.76	-1.17	-0.85	-0.68	-0.9
Change in Investments	-8.65	-3.78	14.45	-19.72	10.1	38.04
Investing Cash Flow	-9.2	-4.54	13.27	-20.57	9.42	37.14
Share Issuance / Repurchase	8.18	8.45	0.03	30.07	18.72	0
Debt Issued / Paid	-0.86	-0.84	9.2	-0.58	-0.64	-0.6
Other Financing Activities	10.41	10.54	0.12	0.79	2.3	9.9
Financing Cash Flow	17.73	18.15	9.34	30.28	20.37	9.31
Exchange Rate Effect	-0.17	-0.25	-2.28	1.1	1.21	0.16
Net Cash Flow	-11.09	-8.21	-3.35	-13.9	11.48	28.94
Free Cash Flow	-20	-22.34	-24.85	-25.56	-20.2	-18.57
Free Cash Flow Margin	-217.65%	-396.03%	-1483.52%	-2748.71%	-1941.92%	-2465.60%
Free Cash Flow Per Share	-0.40	-0.49	-0.60	-0.63	-0.72	-0.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).